Briefly, patients with advanced melanoma or NSCLC who had received systemic anti–PD-1–based immunotherapy or chemoimmunotherapy had undergone dietary history evaluation using DHQ III, had received treatment for at least 3 months, had at least one post-treatment imaging study evaluable for response, had adequate follow-up time (6 months), and had provided informed consent were included (Fig. 1A; Supplementary Fig. S1A). This evidence concerns the gene PDCD1 and melanoma.